108115-66-8

Basic information

• Product Name: ethyl 3-(4-fuoroanilino)-2-(2,4,5-trifuorobenzoyl)acrylate
• Synonyms: ethyl 3-(4-fuoroanilino)-2-(2,4,5-trifuorobenzoyl)acrylate
• CAS NO: 108115-66-8
• Molecular Weight: 367.3
• Mol File: 108115-66-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: ethyl 3-(4-fuoroanilino)-2-(2,4,5-trifuorobenzoyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(4-fuoroanilino)-2-(2,4,5-trifuorobenzoyl)acrylate(108115-66-8)
• EPA Substance Registry System: ethyl 3-(4-fuoroanilino)-2-(2,4,5-trifuorobenzoyl)acrylate(108115-66-8)

Safety Data

• Hazardous Substances Data: 108115-66-8(Hazardous Substances Data)

Upstream product

• 98349-24-7 ethyl 2,4,5-trifluorobenzoylacetate 
• 122-51-0 orthoformic acid triethyl ester 
• 371-40-4 4-fluoroaniline 
• 446-17-3 2,4,5-trifluorobenzoic acid 
• 101799-75-1 α-(ethoxymethylene)-2,4,5-trifluoro-β-oxobenzenepropanoic acid, ethyl ester 

Downstream Products

• 98106-17-3 difloxacin 
• 98105-99-8 sarafloxacin 
• 103994-99-6 6,7-difluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid 
• 108138-16-5 1-(p-fluorophenyl)-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

Synthesis of [1-15N,2-13C]-labeled difloxacin

The synthesis of [1-15N,2-13C]-difloxacin, an arylfluoroquinolone antibacterial agent, is reported. As a crucial initial step, the starting materials ethyl 2,4,5-trifluorobenzoylacetate, [formyl- 13C]-triethyl orthoformate, and [15N]-4-fluoroaniline were reacted to ethyl [15N,3-13C]-3-(4-fluoroanilino)-2-(2,4, 5-trifluorobenzoyl)acrylate. After cyclization and ester cleavage, the resulting intermediate was reacted with 1-methylpiperazine to [1-15N,2- 13C]-1-(4-fluorophenyl)-6-fluoro-7-(4-methyl-1-piperazinyl)-1, 4-dihydro-4-oxoquinoline-3-carboxylate, i.e., [1-15N,2- 13C]-difloxacin. The overall yield was 62% based on the non-labeled and 43% based on the labeled starting materials (both used in 1.4 molar excess). The product was identified by 1H-, 13C-, and 15N-NMR spectroscopy and by cochromatography (TLC, HPLC) with an authentic reference; its purity (HPLC) was above 98%. Prior to synthesis of [1-15N,2-13C]-difloxacin, non-labeled difloxacin was synthesized in order to optimize procedures and to identify and characterize all intermediates.